BlueCross BlueShield Arizona

An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA	**ORIGINAL EFFECTIVE DATE: 04/02/24**
SECTION: LABORATORY	**LAST REVIEW DATE: 04/02/24**
	CURRENT EFFECTIVE DATE: 04/02/24
	LAST CRITERIA REVISION DATE: 04/02/24
NEXT ANNUAL REVIEW DATE: 2ND QTR 2025	**ARCHIVE DATE:**

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Evidence-Based Criteria must be read in its entirety to determine coverage eligibility, if any.

This Evidence-Based Criteria provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Evidence-Based Criteria are subject to change as new information becomes available.

For purposes of this Evidence-Based Criteria, the terms "experimental" and "investigational" are considered to be interchangeable.

EVIDENCE-BASED CRITERIA	**ORIGINAL EFFECTIVE DATE: 04/02/24**
SECTION: LABORATORY	**LAST REVIEW DATE: 04/02/24**
	CURRENT EFFECTIVE DATE: 04/02/24
	LAST CRITERIA REVISION DATE: 04/02/24
NEXT ANNUAL REVIEW DATE: 2ND QTR 2025	**ARCHIVE DATE:**

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

Description:

Numerous lipid and non-lipid biomarkers have been proposed as potential risk markers for cardiovascular disease (CVD). Biomarkers assessed herein include apolipoprotein B, apolipoprotein AI, apolipoprotein E, B-type natriuretic peptide, cystatin C, fibrinogen, high-density lipoprotein subclass, leptin, low-density lipoprotein subclass, lipoprotein(a), and lipoprotein-associated phospholipase A_2(Lp-PLA_2). These biomarkers have been studied as alternatives or additions to standard lipid panels for risk stratification in CVD or as treatment targets for lipid-lowering therapy. Cardiovascular risk panels refer to different combinations of cardiac markers that are intended to evaluate the risk of CVD. There are numerous commercially available risk panels that include different combinations of lipids, noncardiac biomarkers, measures of inflammation, metabolic parameters, and/or genetic markers. Risk panels report the results of multiple individual tests, as distinguished from quantitative risk scores that combine the results of multiple markers into a single score.

A simple lipid panel is generally composed of the following lipid measures:

- Total cholesterol
- Low-density lipoprotein cholesterol
- High-density lipoprotein cholesterol
- Triglycerides

Certain calculated ratios (e.g., total/high-density lipoprotein cholesterol) may also be reported as part of a simple lipid panel.

Other types of lipid testing (i.e., apolipoproteins, lipid particle number or particle size, lipoprotein [a]) are not considered components of a simple lipid profile.

Cardiovascular Disease
Cardiovascular disease (CVD) remains the single largest cause of morbidity and mortality in the developed world. As a result, accurate prediction of CVD risk is a component of medical care that has the potential to focus on and direct preventive and diagnostic activities. Current methods of risk prediction in use in general clinical care are not highly accurate and, as a result, there is a potential unmet need for improved risk prediction instruments.

Risk Assessment
Although treatment for elevated coronary disease risk with statins targets cholesterol levels, selection for treatment involves estimation of future coronary artery disease (CAD) risk using well-validated prediction models that use additional variables.

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

Components of CVD risk include family history, cigarette smoking, hypertension, and lifestyle factors such as diet and exercise. Also, numerous laboratory tests have been associated with CVD risk, most prominently lipids such as low-density lipoprotein (LDL) and high-density lipoprotein (HDL). These clinical and lipid factors are often combined into simple risk prediction instruments, such as the Framingham Risk Score. The Framingham Risk Score provides an estimate of the 10-year risk for developing cardiac disease and is currently used in clinical care to determine the aggressiveness of risk factor intervention, such as the decision to treat hyperlipidemia with statins.

Many additional biomarkers, genetic factors, and radiologic measures have been associated with an increased risk of CVD. Over 100 emerging risk factors have been proposed as useful for refining estimates of CVD risk. Some general categories of these potential risk factors are as follows:

- Lipid markers. In addition to LDL and HDL, other lipid markers may have predictive ability, including the apolipoproteins, lipoprotein (a) (Lp[a]), lipid subfractions, and/or other measures.
- Inflammatory markers. Many measures of inflammation have been linked to the likelihood of CVD. High-sensitivity C-reactive protein (hs-CRP) is an example of an inflammatory marker; others include fibrinogen, interleukins, and tumor necrosis factor.
- Metabolic syndrome biomarkers. Measures associated with metabolic syndromes, such as specific dyslipidemic profiles or serum insulin levels, have been associated with an increased risk of CVD.
- Genetic markers. A number of variants associated with increased thrombosis risk, such as the 5,10-methylene tetrahydrofolate reductase (MTHFR) variant or the prothrombin gene variants, have been associated with increased CVD risk. Also, numerous single nucleotide variants have been associated with CVD in large genome-wide studies.

Risk Panel Testing

CVD risk panels may contain measures from 1 or all of the previous categories and may include other measures not previously listed such as radiologic markers (carotid medial thickness, coronary artery calcium score). Some CVD risk panels are relatively limited, including a few markers in addition to standard lipids. Others include a wide variety of potential risk factors from a number of different categories, often including both genetic and nongenetic risk factors. Other panels are composed entirely of genetic markers.

Some examples of commercially available CVD risk panels are as follows:

- CV Health Plus Genomics™ Panel
- CV Health Plus™ Panel
- CVD Inflammatory Profile
- Applied Genetics Cardiac Panel
- Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel

EVIDENCE-BASED CRITERIA	**ORIGINAL EFFECTIVE DATE: 04/02/24**
SECTION: LABORATORY	**LAST REVIEW DATE: 04/02/24**
	CURRENT EFFECTIVE DATE: 04/02/24
	LAST CRITERIA REVISION DATE: 04/02/24
NEXT ANNUAL REVIEW DATE: 2ND QTR 2025	**ARCHIVE DATE:**

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

In addition to panels that are specifically focused on CVD risk, a number of commercially available panels include markers associated with cardiovascular health, along with a range of other markers that have been associated with inflammation, thyroid disorders and other hormonal deficiencies, and other disorders. An example of these panels is:

- Advanced Health Panel

Multiple assay methods for cardiac risk marker components, such as lipid panels and other biochemical assays, have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process.

In December 2014, the PLAC® Test, a quantitative enzyme assay, was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for Lp-PLA_2 activity. It was considered substantially equivalent to a previous version of the PLAC® Test, which was cleared for marketing by the FDA in July 2003.

Criteria:

- Measurement of non-traditional lipid and non-lipid biomarkers as an adjunct to low-density lipoprotein cholesterol in the risk assessment and management of cardiovascular disease is considered ***experimental or investigational*** when any **ONE** or more of the following criteria are met:

  1. Lack of final approval from the appropriate governmental regulatory bodies (e.g., Food and Drug Administration); or
  2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes; or
  3. Insufficient evidence to support improvement of the net health outcome; or
  4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives; or
  5. Insufficient evidence to support improvement outside the investigational setting.

  These biomarkers include, *but are not limited to:*

  - Apolipoprotein AI
  - Apolipoprotein B
  - Apolipoprotein E
  - B-type natriuretic peptide
  - Cystatin C
  - Fibrinogen
  - High-Density Lipoprotein subclass
  - Leptin
  - Lipoprotein [a]
  - Low Density Lipoprotein subclass

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

- Measurement of lipoprotein-associated phospholipase A_2 is considered ***experimental or investigational*** when any **ONE** or more of the following criteria are met:

  1. Lack of final approval from the appropriate governmental regulatory bodies (e.g., Food and Drug Administration); or
  2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes; or
  3. Insufficient evidence to support improvement of the net health outcome; or
  4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives; or
  5. Insufficient evidence to support improvement outside the investigational setting.

- Cardiovascular disease risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels) are considered ***experimental or investigational*** when any **ONE** or more of the following criteria are met:

  1. Lack of final approval from the appropriate governmental regulatory bodies (e.g., Food and Drug Administration); or
  2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes; or
  3. Insufficient evidence to support improvement of the net health outcome; or
  4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives; or
  5. Insufficient evidence to support improvement outside the investigational setting.

Resources:

Literature reviewed 04/02/24. We do not include marketing materials, poster boards and non-published literature in our review.

Resources prior to 04/02/24 may be requested from the BCBSAZ Medical Policy and Technology Research Department.

1. Ahmadi-Abhari S, Luben RN, Wareham NJ, Khaw KT. Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study. *Eur J Epidemiol*. Jul 2013;28(7):541-50. doi:10.1007/s10654-013-9819-6

2. Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). *J Am Coll Cardiol*. Oct 22 2013;62(17):1575-9. doi:10.1016/j.jacc.2013.06.051

3. Antonopoulos AS, Angelopoulos A, Papanikolaou P, et al. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. *JACC Cardiovasc Imaging*. Mar 2022;15(3):460-471. doi:10.1016/j.jcmg.2021.09.014

4. Arca M, Montali A, Pigna G, et al. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. *Metabolism*. Nov 2007;56(11):1534-41. doi:10.1016/j.metabol.2007.06.021

5. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. Sep 10 2019;140(11):e596-e646. doi:10.1161/cir.0000000000000678

6. Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). *Am J Cardiol*. Feb 15 2013;111(4):506-9. doi:10.1016/j.amjcard.2012.10.037

7. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). *Am J Cardiol*. Mar 15 2003;91(6):667-72. doi:10.1016/s0002-9149(03)00007-9

8. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. *Arterioscler Thromb Vasc Biol*. Mar 2007;27(3):661-70. doi:10.1161/01.ATV.0000255580.73689.8e

9. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. *Arch Intern Med*. Mar 24 2008;168(6):598-608. doi:10.1001/archinte.168.6.598

10. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. *Jama*. Sep 19 2007;298(11):1300-11. doi:10.1001/jama.298.11.1300

11. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. *Circulation*. Oct 8 2002;106(15):1930-7. doi:10.1161/01.cir.0000033222.75187.b9

12. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. *Endocr Pract*. Oct 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002

13. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *Jama*. Mar 28 2012;307(12):1302-9. doi:10.1001/jama.2012.366

14. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol*. Aug 5 2014;64(5):485-94. doi:10.1016/j.jacc.2014.02.615

15. Bolibar I, von Eckardstein A, Assmann G, Thompson S. Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. *Thromb Haemost*. Dec 2000;84(6):955-60.

16. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. *Jama*. Aug 21 1996;276(7):544-8. doi:10.1001/jama.1996.03540070040028

17. Brotman DJ, Walker E, Lauer MS, O'Brien RG. In search of fewer independent risk factors. *Arch Intern Med*. Jan 24 2005;165(2):138-45. doi:10.1001/archinte.165.2.138

18. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med*. Nov 8 1990;323(19):1289-98. doi:10.1056/nejm199011083231901

19. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. *Diabetes Care*. Apr 2008;31(4):811-22. doi:10.2337/dc08-9018

20. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. *Jama*. Sep 26 2001;286(12):1468-74. doi:10.1001/jama.286.12.1468

21. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. *Metabolism*. Jul 1993;42(7):895-901. doi:10.1016/0026-0495(93)90066-w

22. Chiodini BD, Franzosi MG, Barlera S, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. *Eur Heart J*. Aug 2007;28(16):1977-83. doi:10.1093/eurheartj/ehm196

23. Cho S, Lee SH, Park S, et al. The additive value of multiple biomarkers in prediction of premature coronary artery disease. *Acta Cardiol*. Apr 2015;70(2):205-10. doi:10.1080/ac.70.2.3073512

24. Ciftdoğan DY, Coskun S, Ulman C, Tıkız H. The association of apolipoprotein E polymorphism and lipid levels in children with a family history of premature coronary artery disease. *J Clin Lipidol*. Jan-Feb 2012;6(1):81-7. doi:10.1016/j.jacl.2011.06.017

25. Clarke R, Emberson JR, Parish S, et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. *Arch Intern Med*. Jul 9 2007;167(13):1373-8. doi:10.1001/archinte.167.13.1373

26. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med*. Dec 24 2009;361(26):2518-28. doi:10.1056/NEJMoa0902604

27. Curry SJ, Krist AH, Owens DK, et al. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. *Jama*. Jul 17 2018;320(3):272-280. doi:10.1001/jama.2018.8359

28. D'Agostino RB, Sr., Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *Jama*. Jul 11 2001;286(2):180-7. doi:10.1001/jama.286.2.180

29. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. *Jama*. Oct 12 2005;294(14):1799-809. doi:10.1001/jama.294.14.1799

30. de Andrade M, Thandi I, Brown S, Gotto A, Jr., Patsch W, Boerwinkle E. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. *Am J Hum Genet*. Jun 1995;56(6):1379-90.

31. de Lemos JA, Ayers CR, Levine BD, et al. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. *Circulation*. May 30 2017;135(22):2119-2132. doi:10.1161/circulationaha.117.027272

32. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. *Jama*. Jun 20 2012;307(23):2499-506. doi:10.1001/jama.2012.6571

33. Donnelly LA, Palmer CN, Whitley AL, et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. *Pharmacogenet Genomics*. Apr 2008;18(4):279-87. doi:10.1097/FPC.0b013e3282f60aad

34. Eichner JE, Kuller LH, Orchard TJ, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. *Am J Cardiol*. Jan 15 1993;71(2):160-5. doi:10.1016/0002-9149(93)90732-r

35. ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. *Diabetes Care*. Jan 1 2023;46(Suppl 1):S158-s190. doi:10.2337/dc23-S010

36. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *Jama*. Jul 22 2009;302(4):412-23. doi:10.1001/jama.2009.1063

37. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *Jama*. May 16 2001;285(19):2486-97. doi:10.1001/jama.285.19.2486

38. Fogacci F, Cicero AF, D'Addato S, et al. Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. *Eur J Intern Med*. Jan 2017;37:49-55. doi:10.1016/j.ejim.2016.08.018

39. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. *Mayo Clin Proc*. Feb 2007;82(2):159-65. doi:10.4065/82.2.159

40. Genser B, Dias KC, Siekmeier R, Stojakovic T, Grammer T, Maerz W. Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies. *Clin Lab*. 2011;57(3-4):143-56.

41. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. Jun 24 2014;129(25 Suppl 2):S49-73. doi:10.1161/01.cir.0000437741.48606.98

42. Gottlieb SS, Harris K, Todd J, et al. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. *Clin Biochem*. Mar 2015;48(4-5):292-6. doi:10.1016/j.clinbiochem.2014.12.012

43. Gotto AM, Jr., Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Circulation*. Feb 8 2000;101(5):477-84. doi:10.1161/01.cir.101.5.477

44. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Dec 14 2010;56(25):e50-103. doi:10.1016/j.jacc.2010.09.001

45. Greisenegger S, Segal HC, Burgess AI, Poole DL, Mehta Z, Rothwell PM. Biomarkers and mortality after transient ischemic attack and minor ischemic stroke: population-based study. *Stroke*. Mar 2015;46(3):659-66. doi:10.1161/strokeaha.114.007624

46. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. Jul 13 2004;110(2):227-39. doi:10.1161/01.Cir.0000133317.49796.0e

47. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. Jun 18 2019;139(25):e1082-e1143. doi:10.1161/cir.0000000000000625

48. Guarrera S, Fiorito G, Onland-Moret NC, et al. Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction risk. *Clin Epigenetics*. 2015;7:133. doi:10.1186/s13148-015-0164-3

49. Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. *Endocr Pract*. Oct 2020;26(10):1196-1224. doi:10.4158/cs-2020-0490

50. Harari G, Green MS, Magid A, Zelber-Sagi S. Usefulness of Non-High-Density Lipoprotein Cholesterol as a Predictor of Cardiovascular Disease Mortality in Men in 22-Year Follow-Up. *Am J Cardiol*. Apr 15 2017;119(8):1193-1198. doi:10.1016/j.amjcard.2017.01.008

51. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. *Ann Intern Med*. Oct 6 2009;151(7):496-507. doi:10.7326/0003-4819-151-7-200910060-00010

52. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. *Jama*. Aug 15 2007;298(7):776-85. doi:10.1001/jama.298.7.776

53. Ito H, Pacold IV, Durazo-Arvizu R, et al. The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis. *Am J Epidemiol*. Oct 15 2011;174(8):949-57. doi:10.1093/aje/kwr185

54. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. *J Clin Lipidol*. Sep-Oct 2014;8(5):473-88. doi:10.1016/j.jacl.2014.07.007

55. Jellinger PS, Handelsman Y, Rosenblit PD, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. *Endocr Pract*. Apr 2017;23(Suppl 2):1-87. doi:10.4158/ep171764.Appgl

56. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. *Circulation*. Jan 15 2008;117(2):176-84. doi:10.1161/circulationaha.107.715698

57. Kappelle PJ, Gansevoort RT, Hillege JL, Wolffenbuttel BH, Dullaart RP. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. *J Intern Med*. Feb 2011;269(2):232-42. doi:10.1111/j.1365-2796.2010.02323.x

58. Kaptoge S, White IR, Thompson SG, et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. *Am J Epidemiol*. Oct 15 2007;166(8):867-79. doi:10.1093/aje/kwm191

59. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. *Circulation*. Jun 10 2008;117(23):3002-9. doi:10.1161/circulationaha.107.713438

60. Keller T, Boeckel JN, Groß S, et al. Improved risk stratification in prevention by use of a panel of selected circulating microRNAs. *Sci Rep*. Jul 3 2017;7(1):4511. doi:10.1038/s41598-017-04040-w

61. Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD. Fibrinogen and future cardiovascular disease in people with diabetes: aetiological associations and risk prediction using individual participant data from nine community-based prospective cohort studies. *Diab Vasc Dis Res*. Mar 2013;10(2):143-51. doi:10.1177/1479164112451588

62. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation*. Feb 11 2014;129(6):635-42. doi:10.1161/circulationaha.113.004406

63. Koch W, Hoppmann P, Schömig A, Kastrati A. Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. *Int J Cardiol*. Mar 28 2008;125(1):116-7. doi:10.1016/j.ijcard.2007.01.012

64. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. *Arterioscler Thromb Vasc Biol*. Jul 1 2002;22(7):1175-80. doi:10.1161/01.atv.0000022015.97341.3a

65. Kulminski AM, Ukraintseva SV, Arbeev KG, et al. Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men. *J Am Geriatr Soc*. Mar 2008;56(3):478-83. doi:10.1111/j.1532-5415.2007.01574.x

66. Kunutsor SK, Bakker SJ, James RW, Dullaart RP. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. *Atherosclerosis*. Feb 2016;245:143-54. doi:10.1016/j.atherosclerosis.2015.12.021

67. Kwiterovich PO, Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. *Am J Cardiol*. Oct 17 2002;90(8a):30i-47i. doi:10.1016/s0002-9149(02)02749-2

68. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. *Circulation*. Aug 1 1996;94(3):273-8. doi:10.1161/01.cir.94.3.273

69. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. *Circulation*. Jan 7 1997;95(1):69-75. doi:10.1161/01.cir.95.1.69

70. Lara J, Cooper R, Nissan J, et al. A proposed panel of biomarkers of healthy ageing. *BMC Med*. Sep 15 2015;13:222. doi:10.1186/s12916-015-0470-9

71. Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. *Circ Cardiovasc Qual Outcomes*. Nov 2010;3(6):675-83. doi:10.1161/circoutcomes.110.957696

72. Lee SR, Prasad A, Choi YS, et al. LPA Gene, Ethnicity, and Cardiovascular Events. *Circulation*. Jan 17 2017;135(3):251-263. doi:10.1161/circulationaha.116.024611

73. Luo J, Wang LP, Hu HF, et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis. *Clin Chim Acta*. Oct 23 2015;450:39-45. doi:10.1016/j.cca.2015.07.016

74. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. Jan 1 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455

75. Malachias MVB, Jhund PS, Claggett BL, et al. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. *J Am Heart Assoc*. Oct 20 2020;9(19):e017462. doi:10.1161/jaha.120.017462

76. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. *Jama*. Jul 1 2009;302(1):49-57. doi:10.1001/jama.2009.943

77. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. *Circulation*. Mar 15 2005;111(10):1233-41. doi:10.1161/01.Cir.0000158136.76824.04

78. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. *Circulation*. Nov 1 1996;94(9):2146-53. doi:10.1161/01.cir.94.9.2146

79. Mohebi R, van Kimmenade R, McCarthy CP, et al. Performance of a multi-biomarker panel for prediction of cardiovascular event in patients with chronic kidney disease. *Int J Cardiol*. Jan 15 2023;371:402-405. doi:10.1016/j.ijcard.2022.09.074

80. Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). *J Am Coll Cardiol*. Apr 24 2012;59(17):1521-8. doi:10.1016/j.jacc.2011.12.035

81. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. *Circulation*. Sep 10 2013;128(11):1189-97. doi:10.1161/circulationaha.113.002671

82. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. *Circulation*. Feb 24 2009;119(7):931-9. doi:10.1161/circulationaha.108.816181

83. Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. *Circulation*. Apr 24 2012;125(16):1979-87. doi:10.1161/circulationaha.111.088591

84. National Heart Lung and Blood Institute. Managing Blood Cholesterol in Adults: Systematic Evidence Review From the Cholesterol Expert Panel, 2013. Bethesda, MD: National Heart, Lung, and Blood Institute. 2013. Accessed November 3, 2023. https://www.nhlbi.nih.gov/sites/default/files/media/docs/cholesterol-in-adults.pdf

85. National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification [CG181]. Updated May 2023. Accessed November 3, 2023. https://www.nice.org.uk/guidance/cg181

86. National Institutes of Health National Heart Lung and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (NIH Publication No. 01-3670). Accessed November 17, 2023. https://www.nhlbi.nih.gov/files/docs/guidelines/atp3xsum.pdf

87. Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. *Arterioscler Thromb Vasc Biol*. Dec 2013;33(12):2902-8. doi:10.1161/atvbaha.113.302479

88. Niakouei A, Tehrani M, Fulton L. Health Disparities and Cardiovascular Disease. *Healthcare (Basel)*. Mar 22 2020;8(1)doi:10.3390/healthcare8010065

89. Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. *Jama*. Jan 15 2014;311(3):252-62. doi:10.1001/jama.2013.282836

90. O'Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. *Jama*. Sep 10 2014;312(10):1006-15. doi:10.1001/jama.2014.11061

91. Ohira T, Schreiner PJ, Morrisett JD, Chambless LE, Rosamond WD, Folsom AR. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. *Stroke*. Jun 2006;37(6):1407-12. doi:10.1161/01.STR.0000222666.21482.b6

92. Ordovas JM, Mooser V. The APOE locus and the pharmacogenetics of lipid response. *Curr Opin Lipidol*. Apr 2002;13(2):113-7. doi:10.1097/00041433-200204000-00001

93. Osei-Hwedieh DO, Amar M, Sviridov D, Remaley AT. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. *Pharmacol Ther*. Apr 2011;130(1):83-91. doi:10.1016/j.pharmthera.2010.12.003

94. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. *Am J Cardiol*. Oct 17 2002;90(8a):22i-29i. doi:10.1016/s0002-9149(02)02632-2

95. Patterson CC, Blankenberg S, Ben-Shlomo Y, et al. Which biomarkers are predictive specifically for cardiovascular or for non-cardiovascular mortality in men? Evidence from the Caerphilly Prospective Study (CaPS). *Int J Cardiol*. Dec 15 2015;201:113-8. doi:10.1016/j.ijcard.2015.07.106

96. Paynter NP, Chasman DI, Paré G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. *Jama*. Feb 17 2010;303(7):631-7. doi:10.1001/jama.2010.119

97. Pencina MJ, D'Agostino RB, Zdrojewski T, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. *Eur J Prev Cardiol*. Oct 2015;22(10):1321-7. doi:10.1177/2047487315569411

98. Perera R, McFadden E, McLellan J, et al. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. *Health Technol Assess*. Dec 2015;19(100):1-401, vii-viii. doi:10.3310/hta191000

99. Rasouli M, Kiasari AM, Mokhberi V. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. *Clin Chem Lab Med*. 2006;44(8):1015-21. doi:10.1515/cclm.2006.163

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

100. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. *Arterioscler Thromb Vasc Biol*. Mar 2009;29(3):424-30. doi:10.1161/atvbaha.108.181735

101. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *Jama*. Feb 14 2007;297(6):611-9. doi:10.1001/jama.297.6.611

102. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. *Jama*. Nov 10 1993;270(18):2195-9.

103. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. *Jama*. Jul 20 2005;294(3):326-33. doi:10.1001/jama.294.3.326

104. Rigal M, Ruidavets JB, Viguier A, et al. Lipoprotein (a) and risk of ischemic stroke in young adults. *J Neurol Sci*. Jan 15 2007;252(1):39-44. doi:10.1016/j.jns.2006.10.004

105. Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. *Am J Cardiol*. Nov 15 2012;110(10):1468-76. doi:10.1016/j.amjcard.2012.07.007

106. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. *Am J Cardiol*. Jul 15 2002;90(2):89-94. doi:10.1016/s0002-9149(02)02427-x

107. Rosenson RS, Underberg JA. Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. *Cardiovasc Drugs Ther*. Oct 2013;27(5):465-79. doi:10.1007/s10557-013-6477-6

108. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. *Diabetes Care*. Aug 2007;30(8):1945-51. doi:10.2337/dc07-0015

109. Safo SE, Haine L, Baker J, et al. Derivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort. *J Am Heart Assoc*. Jul 4 2023;12(13):e027273. doi:10.1161/jaha.122.027273

110. Sarkkinen E, Korhonen M, Erkkilä A, Ebeling T, Uusitupa M. Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. *Am J Clin Nutr*. Dec 1998;68(6):1215-22. doi:10.1093/ajcn/68.6.1215

111. Sattar N, Wannamethee G, Sarwar N, et al. Leptin and coronary heart disease: prospective study and systematic review. *J Am Coll Cardiol*. Jan 13 2009;53(2):167-75. doi:10.1016/j.jacc.2008.09.035

112. Şaylık F, Akbulut T. Temporal relationship between serum calcium and triglyceride-glucose index and its impact on the incident of the acute coronary syndrome: a cross-lagged panel study. *Acta Cardiol*. Jul 2023;78(5):586-593. doi:10.1080/00015385.2022.2106017

113. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. *Jama*. Apr 6 1994;271(13):999-1003. doi:10.1001/jama.1994.03510370051031

114. Schmitz F, Mevissen V, Krantz C, et al. Robust association of the APOE epsilon4 allele with premature myocardial infarction especially in patients without hypercholesterolaemia: the Aachen study. *Eur J Clin Invest*. Feb 2007;37(2):106-8. doi:10.1111/j.1365-2362.2007.01764.x

115. Schoe A, Schippers EF, Ebmeyer S, et al. Predicting mortality and morbidity after elective cardiac surgery using vasoactive and inflammatory biomarkers with and without the EuroSCORE model. *Chest*. Nov 2014;146(5):1310-1318. doi:10.1378/chest.13-2615

116. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*. Sep 4 2001;104(10):1108-13. doi:10.1161/hc3501.095214

117. Shaw LJ, Polk DM, Kahute TA, et al. Prognostic accuracy of B-natriuretic peptide measurements and coronary artery calcium in asymptomatic subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study). *Am J Cardiol*. Nov 1 2009;104(9):1245-50. doi:10.1016/j.amjcard.2009.06.041

118. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? *Circulation*. Mar 12 2002;105(10):1162-9. doi:10.1161/hc1002.105136

119. Singh K, Chandra A, Sperry T, et al. Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. *Circulation*. Aug 18 2020;142(7):657-669. doi:10.1161/circulationaha.120.045713

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

120. Sirtori CR, Calabresi L, Pisciotta L, et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. *Nutr Metab Cardiovasc Dis*. Feb 2005;15(1):47-55. doi:10.1016/j.numecd.2004.08.001

121. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. *Stroke*. Jun 2007;38(6):1959-66. doi:10.1161/strokeaha.106.480657

122. Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. *Atherosclerosis*. Dec 2012;225(2):444-9. doi:10.1016/j.atherosclerosis.2012.08.039

123. Sofat R, Cooper JA, Kumari M, et al. Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies. *PLoS Med*. Oct 2016;13(10):e1002146. doi:10.1371/journal.pmed.1002146

124. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. *Jama*. Sep 18 1996;276(11):882-8.

125. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Jul 1 2014;63(25 Pt B):2889-934. doi:10.1016/j.jacc.2013.11.002

126. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. *J Am Coll Cardiol*. Jul 8 2008;52(2):124-31. doi:10.1016/j.jacc.2008.04.009

127. Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. *Am J Cardiol*. Nov 1 2005;96(9):1266-72. doi:10.1016/j.amjcard.2005.06.069

128. Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. *J Am Heart Assoc*. Apr 14 2014;3(2):e000759. doi:10.1161/jaha.113.000759

129. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. *Lancet*. May 1 2010;375(9725):1536-44. doi:10.1016/s0140-6736(10)60319-4

130. Thorne. Advanced Health Panel. Accessed October 16, 2023. https://www.thorne.com/products/dp/advanced-health-panel

131. Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. *J Atheroscler Thromb*. Jun 2007;14(3):128-32. doi:10.5551/jat.14.128

132. Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. *Atherosclerosis*. Aug 2014;235(2):585-91. doi:10.1016/j.atherosclerosis.2014.05.914

133. Tzou WS, Douglas PS, Srinivasan SR, Chen W, Berenson G, Stein JH. Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. *Ann Intern Med*. May 3 2005;142(9):742-50. doi:10.7326/0003-4819-142-9-200505030-00009

134. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. *Circulation*. Apr 24 2007;115(16):2119-27. doi:10.1161/circulationaha.106.635029

135. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. *JAMA Intern Med*. Apr 22 2013;173(8):664-71. doi:10.1001/jamainternmed.2013.3018

136. Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. *Clin Biochem*. Oct 2007;40(15):1150-6. doi:10.1016/j.clinbiochem.2007.06.010

137. van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. *Ann Intern Med*. May 1 2007;146(9):640-8. doi:10.7326/0003-4819-146-9-200705010-00007

138. van Holten TC, Waanders LF, de Groot PG, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. *PLoS One*. 2013;8(4):e62080. doi:10.1371/journal.pone.0062080

139. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. *Heart*. Aug 2003;89(8):893-6. doi:10.1136/heart.89.8.893

140. Vasunilashorn S, Glei DA, Lan CY, Brookmeyer R, Weinstein M, Goldman N. Apolipoprotein E is associated with blood lipids and inflammation in Taiwanese older adults. *Atherosclerosis*. Nov 2011;219(1):349-54. doi:10.1016/j.atherosclerosis.2011.07.100

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

141. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. Sep 7 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484

142. Volcik KA, Barkley RA, Hutchinson RG, et al. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. *Am J Epidemiol*. Aug 15 2006;164(4):342-8. doi:10.1093/aje/kwj202

143. Vossen CY, Hoffmann MM, Hahmann H, Wüsten B, Rothenbacher D, Brenner H. Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. *Clin Pharmacol Ther*. Aug 2008;84(2):222-7. doi:10.1038/clpt.2008.31

144. Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. *Eur Heart J*. Aug 21 2017;38(32):2490-2498. doi:10.1093/eurheartj/ehx166

145. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. *J Intern Med*. Feb 2004;255(2):188-205. doi:10.1046/j.1365-2796.2003.01276.x

146. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. *Lancet*. Dec 15 2001;358(9298):2026-33. doi:10.1016/s0140-6736(01)07098-2

147. Wallentin L, Eriksson N, Olszowka M, et al. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. *PLoS Med*. Jan 2021;18(1):e1003513. doi:10.1371/journal.pmed.1003513

148. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*. Feb 12 2004;350(7):655-63. doi:10.1056/NEJMoa031994

149. Welsh P, Kou L, Yu C, et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. *Eur J Heart Fail*. Feb 2018;20(2):268-277. doi:10.1002/ejhf.988

150. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. *N Engl J Med*. May 1 2014;370(18):1702-11. doi:10.1056/NEJMoa1315878

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

151. Willeit P, Thompson SG, Agewall S, et al. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. *Eur J Prev Cardiol*. Jan 2016;23(2):194-205. doi:10.1177/2047487314560664

152. Willis A, Davies M, Yates T, Khunti K. Primary prevention of cardiovascular disease using validated risk scores: a systematic review. *J R Soc Med*. Aug 2012;105(8):348-56. doi:10.1258/jrsm.2012.110193

153. Wilsgaard T, Mathiesen EB, Patwardhan A, et al. Clinically significant novel biomarkers for prediction of first ever myocardial infarction: the Tromsø Study. *Circ Cardiovasc Genet*. Apr 2015;8(2):363-71. doi:10.1161/circgenetics.113.000630

154. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. *J Clin Lipidol*. May-Jun 2019;13(3):374-392. doi:10.1016/j.jacl.2019.04.010

155. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. *Jama*. Dec 7 1994;272(21):1666-71.

156. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. *Arterioscler Thromb Vasc Biol*. Oct 1996;16(10):1250-5. doi:10.1161/01.atv.16.10.1250

157. Wilson PWF, Jacobson TA, Martin SS, et al. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. *J Clin Lipidol*. Sep-Oct 2021;15(5):629-648. doi:10.1016/j.jacl.2021.09.046

158. Winkel P, Jakobsen JC, Hilden J, et al. Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial. *BMJ Open*. Aug 20 2020;10(8):e033720. doi:10.1136/bmjopen-2019-033720

159. Wu Z, Pilbrow AP, Liew OW, et al. Circulating cardiac biomarkers improve risk stratification for incident cardiovascular disease in community dwelling populations. *EBioMedicine*. Aug 2022;82:104170. doi:10.1016/j.ebiom.2022.104170

160. Wuopio J, Hilden J, Bring C, et al. Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study. *Atherosclerosis*. Nov 2018;278:97-102. doi:10.1016/j.atherosclerosis.2018.09.006

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

161. Yang H, Guo W, Li J, et al. Leptin concentration and risk of coronary heart disease and stroke: A systematic review and meta-analysis. *PLoS One*. 2017;12(3):e0166360. doi:10.1371/journal.pone.0166360

162. Zakai NA, Katz R, Jenny NS, et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. *J Thromb Haemost*. Jun 2007;5(6):1128-35. doi:10.1111/j.1538-7836.2007.02528.x

163. Zeng R, Xu CH, Xu YN, Wang YL, Wang M. Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: a meta-analysis. *Arq Bras Endocrinol Metabol*. Nov 2014;58(8):817-23. doi:10.1590/0004-2730000003390

164. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med*. May 15 2008;358(20):2107-16. doi:10.1056/NEJMoa0707064

Coding:

CPT: 0052U, 0119U, 81291, 81401, 82172, 82397, 82465, 82610, 82652, 82664, 83090, 83695, 83698, 83700, 83701, 83704, 83718, 83721, 83722, 83880, 84181, 84478, 85384, 85385, 86141

History:	Date:	Activity:
Medical Policy Panel	04/02/24	Approved guideline

Policy Revisions:

EVIDENCE-BASED CRITERIA	**ORIGINAL EFFECTIVE DATE: 04/02/24**
SECTION: LABORATORY	**LAST REVIEW DATE: 04/02/24**
	CURRENT EFFECTIVE DATE: 04/02/24
	LAST CRITERIA REVISION DATE: 04/02/24
NEXT ANNUAL REVIEW DATE: 2ND QTR 2025	**ARCHIVE DATE:**

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

Non-Discrimination Statement:

Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services.

If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ's Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ's Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1–800–368–1019, 800–537–7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html

Multi-Language Interpreter Services:

Spanish: Si usted, o alguien a quien usted está ayudando, tiene preguntas acerca de Blue Cross Blue Shield of Arizona, tiene derecho a obtener ayuda e información en su idioma sin costo alguno. Para hablar con un intérprete, llame al 602-864-4884.

Navajo: Díí kwe'é atah nílínigíí Blue Cross Blue Shield of Arizona haada yit'éego bína'ídíłkidgo éí doodago Háida bíjá anilyeedígíí t'áadoo le'é yína'ídíłkidgo beehaz'áanii hóló díí t'áá hazaadk'ehjí háká a'doowołgo bee haz'ą doo bąąh íłínígóó. Ata' halne'ígíí kojį' bich'į' hodíilnih 877-475-4799.

Chinese: 如果您，或是您正在協助的對象，有關於插入項目的名稱 Blue Cross Blue Shield of Arizona 方面的問題，您有權利免費以您的母語得到幫助和訊息。洽詢一位翻譯員，請撥電話 在此插入數字 877-475-4799。

Vietnamese: Nếu quý vị, hay người mà quý vị đang giúp đỡ, có câu hỏi về Blue Cross Blue Shield of Arizona quý vị sẽ có quyền được giúp và có thêm thông tin bằng ngôn ngữ của mình miễn phí. Để nói chuyện với một thông dịch viên, xin gọi 877-475-4799.

Arabic:
إن كان لديك أو لدى شخص تساعده أسئلة بخصوص Blue Cross Blue Shield of Arizona، فلديك الحق في الحصول على المساعدة والمعلومات الضرورية بلغتك من دون اية تكلفة. للتحدث مع مترجم اتصل ب 877-475-4799.

BIOMARKER TESTING IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

Multi-Language Interpreter Services:

Tagalog: Kung ikaw, o ang iyong tinutulangan, ay may mga katanungan tungkol sa Blue Cross Blue Shield of Arizona, may karapatan ka na makakuha ng tulong at impormasyon sa iyong wika ng walang gastos. Upang makausap ang isang tagasalin, tumawag sa 877-475-4799.

Korean: 만약 귀하 또는 귀하가 돕고 있는 어떤 사람이 Blue Cross Blue Shield of Arizona 에 관해서 질문이 있다면 귀하는 그러한 도움과 정보를 귀하의 언어로 비용 부담없이 얻을 수 있는 권리가 있습니다. 그렇게 통역사와 얘기하기 위해서는 877-475-4799 로 전화하십시오.

French: Si vous, ou quelqu'un que vous êtes en train d'aider, a des questions à propos de Blue Cross Blue Shield of Arizona, vous avez le droit d'obtenir de l'aide et l'information dans votre langue à aucun coût. Pour parler à un interprète, appelez 877-475-4799.

German: Falls Sie oder jemand, dem Sie helfen, Fragen zum Blue Cross Blue Shield of Arizona haben, haben Sie das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Um mit einem Dolmetscher zu sprechen, rufen Sie bitte die Nummer 877-475-4799 an.

Russian: Если у вас или лица, которому вы помогаете, имеются вопросы по поводу Blue Cross Blue Shield of Arizona, то вы имеете право на бесплатное получение помощи и информации на вашем языке. Для разговора с переводчиком позвоните по телефону 877-475-4799.

Japanese: ご本人様、またはお客様の身の回りの方でも、Blue Cross Blue Shield of Arizona についてご質問がございましたら、ご希望の言語でサポートを受けたり、情報を入手したりすることができます。料金はかかりません。通訳とお話される場合、877-475-4799 までお電話ください。

Farsi:

اگر شما، یا کسی که شما به او کمک میکنید ، سوال در مورد Blue Cross Blue Shield of Arizona ، داشته باشید حق این را دارید که کمک و اطلاعات به زبان خود را به طور رایگان دریافت نمایید 877-475-4799
[تماس حاصل نمایید.

Assyrian:

[illegible] Blue Cross Blue Shield of Arizona [illegible]
[illegible] 877-475-4799.

Serbo-Croatian: Ukoliko Vi ili neko kome Vi pomažete ima pitanje o Blue Cross Blue Shield of Arizona, imate pravo da besplatno dobijete pomoć i informacije na Vašem jeziku. Da biste razgovarali sa prevodiocem, nazovite 877-475-4799.

Thai: หากคณ หรอคนทคณกาลงชวยเหลอมคาถามเกยวกบ Blue Cross Blue Shield of Arizona คณมสทธทจะไดรบความชวยเหลอและขอมลในภาษา ของคณไดโดยไมมคาใชจาย พดคยกบลาม โทร 877-475-4799